By Fineline Cube 
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19 (IL-23p19) inhibitor, has entered Phase 3 clinical trials for psoriasis and Crohn’s disease. This milestone highlights the progress of the drug in addressing significant unmet medical needs in autoimmune conditions.
Licensing Agreement
In April 2024, Qyuns entered into an exclusive outlicensing agreement with Hansoh (Shanghai) Healthtech Co., Ltd. The agreement covers the research and development, manufacturing, and commercialization of QX004N within mainland China, Taiwan, Hong Kong, and Macau.
Recent Payments
Recently, Qyuns received payments totaling RMB 58.0 million from Hansoh as per the license agreement. This includes milestone payments for reaching Phase 3 in psoriasis development and other agreed-upon terms.-Fineline Info & Tech